You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Details for New Drug Application (NDA): 210300


✉ Email this page to a colleague

« Back to Dashboard


NDA 210300 describes ERLOTINIB HYDROCHLORIDE, which is a drug marketed by Accord Hlthcare, Alembic, Apotex, Chartwell Rx, Eugia Pharma, Hetero Labs Ltd V, MSN, Natco Pharma Ltd, Rising, Shilpa, Sun Pharm, Teva Pharms Usa Inc, and Zydus Pharms, and is included in thirteen NDAs. It is available from twelve suppliers. Additional details are available on the ERLOTINIB HYDROCHLORIDE profile page.

The generic ingredient in ERLOTINIB HYDROCHLORIDE is erlotinib hydrochloride. There are twenty-five drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the erlotinib hydrochloride profile page.
Summary for 210300
Tradename:ERLOTINIB HYDROCHLORIDE
Applicant:Sun Pharm
Ingredient:erlotinib hydrochloride
Patents:0
Pharmacology for NDA: 210300
Mechanism of ActionProtein Kinase Inhibitors
Medical Subject Heading (MeSH) Categories for 210300
Suppliers and Packaging for NDA: 210300
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ERLOTINIB HYDROCHLORIDE erlotinib hydrochloride TABLET;ORAL 210300 ANDA Sun Pharmaceutical Industries, Inc. 63304-095 63304-095-11 3 BLISTER PACK in 1 CARTON (63304-095-11) / 10 TABLET, FILM COATED in 1 BLISTER PACK (63304-095-31)
ERLOTINIB HYDROCHLORIDE erlotinib hydrochloride TABLET;ORAL 210300 ANDA Sun Pharmaceutical Industries, Inc. 63304-095 63304-095-30 30 TABLET, FILM COATED in 1 BOTTLE (63304-095-30)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 25MG BASE
Approval Date:Nov 5, 2019TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 100MG BASE
Approval Date:Nov 5, 2019TE:ABRLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 150MG BASE
Approval Date:Nov 5, 2019TE:ABRLD:No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.